Answers are grounded in this paper and cite their sources.
Analysis reveals that clozapine augmentation with SSRIs or SNRIs significantly lowers relapse in treatment-resistant schizophrenia, suggesting effective treatment strategies.
An analysis based on data from two national cohort studies has found that augmentation of clozapine treatment with a selective serotonin reuptake inhibitor (SSRI) or serotonin‐norepinephrine reuptake inhibitor (SNRI) reduces risk of relapse in patients with treatment‐resistant schizophrenia. Augmentation with other antidepressants did not reduce risk of relapse, and the beneficial effects of SSRIs and SNRIs were observed only at low or standard doses of the antidepressants.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: